[Extrapulmonary tuberculosis].
Ketata W, Rekik WK, Ayadi H, Kammoun S.
Rev Pneumol Clin. 2015 Apr-Jun;71(2-3):83-92. doi: 10.1016/j.pneumo.2014.04.001. Epub 2014 Aug 15.
Pathogenesis of tuberculosis and other mycobacteriosis.
Cardona PJ.
Enferm Infecc Microbiol Clin (Engl Ed). 2018 Jan;36(1):38-46. doi: 10.1016/j.eimc.2017.10.015. Epub 2017 Dec 2.
Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines.
Schito M, Migliori GB, Fletcher HA, McNerney R, Centis R, D'Ambrosio L, Bates M, Kibiki G, Kapata N, Corrah T, Bomanji J, Vilaplana C, Johnson D, Mwaba P, Maeurer M, Zumla A.
Clin Infect Dis. 2015 Oct 15;61Suppl 3(Suppl 3):S102-18. doi: 10.1093/cid/civ609.
Present epidemiology of tuberculosis. Prevention and control programs.
Orcau À, Caylà JA, Martínez JA.
Enferm Infecc Microbiol Clin. 2011 Mar;29 Suppl 1:2-7. doi: 10.1016/S0213-005X(11)70011-8.
[Tuberculosis 2006].
Strausz J.
Orv Hetil. 2007 May 6;148(18):829-31. doi: 10.1556/OH.2007.28057.
[Multidrug-resistant tuberculosis].
Bouvet E.
Presse Med. 1996 Mar 2-9;25(8):393-8.
Reactivation or reinfection in adult tuberculosis: Is that the question?
Cardona PJ.
Int J Mycobacteriol. 2016 Dec;5(4):400-407. doi: 10.1016/j.ijmyco.2016.09.017. Epub 2016 Oct 27.
Inactive fibrotic lesions versus pulmonary tuberculosis with negative bacteriology.
Solsona Peiró J, de Souza Galvão ML, Altet Gómez MN.
Arch Bronconeumol. 2014 Nov;50(11):484-9. doi: 10.1016/j.arbres.2013.07.009. Epub 2014 Apr 6.
[Managing multidrug-resistant tuberculosis].
Antoun F, Véziris N.
Rev Mal Respir. 2011 Oct;28(8):956-7. doi: 10.1016/j.rmr.2011.06.010. Epub 2011 Oct 12.
Cost-effectiveness of active tuberculosis screening among high-risk populations in low tuberculosis incidence countries: a systematic review, 2008 to 2023.
Gogichadze N, Sagrera A, Vicente JÁ, Millet JP, López-Seguí F, Vilaplana C.
Euro Surveill. 2024 Mar;29(12):2300614. doi: 10.2807/1560-7917.ES.2024.29.12.2300614.
